Summary Glucagon-like peptide 1 (GLP-1) is a gut-derived incretin hormone that stimulates
insulin and suppresses glucagon secretion, inhibits gastric emptying, and reduces appetite …

Gut peptides, exemplified by glucagon-like peptide-1 (GLP-1) and glucose-dependent
insulinotropic polypeptide (GIP) are secreted in a nutrient-dependent manner and stimulate …

OBJECTIVE—The purpose of this study was to establish whether hypoglycemia after gastric
bypass surgery (GBS) for morbid obesity is due to increased fractional β-cell area or …

Glucagon-like peptide-1 is an insulinotropic hormone with antidiabetic potential due to its
spectrum of effects, which include glucose-dependent stimulation of insulin and inhibition of …

Glucagon-like peptide 1 (GLP-1) lowers glycemia by modulating gastric emptying and
endocrine pancreatic secretion. Rapidly after its secretion, GLP-1-(7–36) amide is degraded …

Exenatide is a glucagon-like peptide 1 receptor agonist, which has recently received FDA
approval in the US for the treatment of Type 2 diabetes. Exenatide is an incretin mimetic that …

A series of (5-substituted pyrrolidinyl-2-carbonyl)-2-cyanopyrrolidine (C5-Pro-Pro)
analogues was discovered as dipeptidyl peptidase IV (DPPIV) inhibitors as a potential …

AIM: To review the role that glucagon plays in physiology, physiopathology and clinical
medicine. DATA SYNTHESIS: Glucagon assays employing specific radioimmunoassay …

This review article describes the regulation of glucose homeostasis in subjects with and
without diabetes based on the emergence of new information and discusses modes of …

The splanchnic bed produces cortisol at rates approximating extraadrenal tissues by
converting cortisone to cortisol via the 11β-hydroxysteroid dehydrogenase (11β-HSD) type 1 …